BioSpace News Archive

Business

McKesson Corporation Announces Fourth-quarter Fiscal 2023 Earnings Release Date

McKesson Corporation will release its fourth-quarter and full-year fiscal 2023 financial results after market close on Monday, May 8, 2023.

March 27, 2023
·
1 min read
Drug Development

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.

March 27, 2023
·
17 min read
Drug Development

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γD2 T cell therapy against EGFR-expressing solid tumors

Acepodia announced the upcoming poster presentation of new preclinical data for ACE2016, a gamma delta-2 T cell therapy designed to target EGFR expressing solid tumors.

March 27, 2023
·
3 min read
Genetown

Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea

Biophytis SA announced that it has held a presentation on their drug candidate, Sarconeos, as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research.

March 27, 2023
·
5 min read
Pharm Country

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics, Inc. today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.

March 27, 2023
·
1 min read
FDA

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-617.

March 27, 2023
·
6 min read
Drug Development

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. today announced it has completed enrollment in the Phase 2 “Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration (wet AMD).

March 27, 2023
·
8 min read
Business

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

Acumen Pharmaceuticals, Inc. today reported financial results for the full year ended December 31, 2022 and provided a business update.

March 27, 2023
·
12 min read
Business

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

BiomX Inc. today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m. ET, to report fourth quarter and full year 2022 financial results and provide business updates.

March 27, 2023
·
1 min read
Covalon Presents New CLABSI Conscious Series Webinar: Protecting CVADs from Gross Contamination

Covalon Technologies Ltd. today announced the second expert-led webinar in its CLABSI Conscious campaign, titled “Protecting CVADs from Gross Contamination”, to be held on Wednesday, March 29 at 1pm EDT.

March 27, 2023
·
4 min read